EC1456 (Folate-Tubulysin) Cancer*
Designed to deliver a highly potent chemotherapy drug to folate-receptor-positive cancers
EC1456 is an investigational, proprietary, injectable SMDC consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1456 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibits the polymerization of tubulin into microtubules, a critical component during cell division. The targeting ligand folate, essential for cell division, has been established in Vynfinit® (vintafolide). EC1456 is the first SMDC with TubBH to enter clinical trials.
EC1456 is being co-developed with Folcepri® (etarfolatide) as its companion imaging agent.
EC1456 is currently being evaluated in a phase 1 study in patients with advanced solid tumors.
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.